HR and breast cancer: A Korean retrospective study performed prior to the establishment of PPS highlighted the prognostic importance of BC molecular subtypes by demonstrating that advanced AS (II-III) HR+/HER2- BC had better recurrence-free survival and OS compared to AS I, unfavorable histology (HER2+ or TN) BC [12].